Distribution of amyloidosis subtypes based on tissue biopsy site − Consecutive analysis of 729 patients at a single amyloidosis center in Japan. Issue 1 (28th October 2020)

• Record Type: Journal Article
• Authors: Abe, Ryuta; Katoh, Nagaaki; Takahashi, Yusuke; Takasone, Ken; Yoshinaga, Tsuneaki; Yazaki, Masahide; Kametani, Fuyuki; Sekijima, Yoshiki
• Is Part Of: Pathology international. Volume 71:Issue 1(2021)
• Page Start: 70
• Page End: 79
• Publication Date: 2020-10-28
• Subjects: amyloidosis subtypes -- biopsy -- diagnosis -- immunoglobulin heavy chain amyloidosis -- immunoglobulin light chain amyloidosis -- immunohistochemistry -- mass spectrometry -- transthyretin amyloidosis; Pathology -- Periodicals; 616.07
• DOI: 10.1111/pin.13041
• Languages: English
• ISSNs: 1320-5463

Abstract

Abstract : This study was performed to elucidate the distribution of amyloidosis subtypes based on tissue biopsy site. Samples obtained from 729 consecutive patients with amyloidosis were analyzed by immunohistochemical staining (IHC) and supplemental mass spectrometry (MS). The correlations between the type of organs from which samples were obtained and amyloidosis subtypes were investigated retrospectively. Among the patients, 95.1% were diagnosed by IHC and 4.9% were diagnosed by MS. The distribution of amyloidosis subtypes was as follows: AL, 59.1%; ATTR, 32.9%; AA, 4.0%; AH, 1.4%; Aβ2M, 0.8%; and others, 0.9%. AL was the most common subtype in most organs, including the liver, lung, kidney, lower urinary tract, bone marrow, gastrointestinal tract, and skin/subcutaneous tissue. ATTR was the most common subtype in the heart, carpal tunnel, and peripheral nerves. AH was the second most common subtype in renal biopsy. Three or more amyloidosis subtypes were detected in each organ. In conclusion, AL was the most common subtype in most biopsy sites except the heart, carpal tunnel, and peripheral nerve, in which ATTR was more common. Because several types of amyloidogenic protein were detected in each organ, amyloid typing must be pursued, no matter the site from where biopsy was obtained.